- 维替索妥尤单抗是中国首个获批针对既往经治的复发或转移性宫颈癌的抗体偶联药物(ADC) - 维替索妥尤单抗在全球3期innovaTV 301临床研究(包括中国亚组数据)中展现出了显著的统计学意义总生存获益 中国上海和美国马萨诸塞州剑桥市2026年6月9日 /美通社/ -- 再鼎医药有限公司(纳斯达克股票代码:ZLAB;香港联交所股份代号:9688)2026年6月8日宣布,国家药品监督管理局(...
Source Link- 维替索妥尤单抗是中国首个获批针对既往经治的复发或转移性宫颈癌的抗体偶联药物(ADC) - 维替索妥尤单抗在全球3期innovaTV 301临床研究(包括中国亚组数据)中展现出了显著的统计学意义总生存获益 中国上海和美国马萨诸塞州剑桥市2026年6月9日 /美通社/ -- 再鼎医药有限公司(纳斯达克股票代码:ZLAB;香港联交所股份代号:9688)2026年6月8日宣布,国家药品监督管理局(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.